Grifols (GIFLF) Other Non-Current Assets (2016 - 2025)
Grifols (GIFLF) reported Other Non-Current Assets of $27.9 million for Q4 2025, down 31.2% on a YoY basis from $40.6 million in Q4 2024, and down 31.2% quarter-over-quarter from $40.6 million in Q4 2024.
Grifols (GIFLF) Other Non-Current Assets (2016 - 2025) Analysis & Trends
Grifols has reported Other Non-Current Assets for 10 years, with the latest figure at $27.9 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets fell 31.2% year-over-year to $27.9 million; the trailing twelve-month figure through Dec 2025 stood at $27.9 million (down 31.2% YoY), and the FY2025 full-year result was $27.9 million, down 31.2% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $27.9 million, down from $40.6 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $298.9 million in Q4 2021, with the low at $27.9 million in Q4 2025.
- Historically, Other Non-Current Assets has averaged $128.0 million across 5 years, with a median of $126.7 million in 2022.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 132.07% — and 2024, when it slumped 72.17%.
- Grifols' Other Non-Current Assets stood at $298.9 million in 2021, then plunged by 57.61% to $126.7 million in 2022, then gained by 15.17% to $145.9 million in 2023, then tumbled by 72.17% to $40.6 million in 2024, then sank by 31.2% to $27.9 million in 2025.
- The last three Other Non-Current Assets figures came in at $27.9 million (Q4 2025), $40.6 million (Q4 2024), and $145.9 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 3.18 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 7.23 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 14.11 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 10.54 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 6.08 Bn |
| 10 | Grifols | - | - | - | 27.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27.94 Mn |
| Dec 31, 2024 | 40.61 Mn |
| Dec 31, 2023 | 145.93 Mn |
| Dec 31, 2022 | 126.71 Mn |
| Dec 31, 2021 | 298.91 Mn |
| Dec 31, 2020 | 128.80 Mn |
| Sep 30, 2020 | 147.64 Mn |
| Mar 31, 2020 | 145.22 Mn |
| Dec 31, 2019 | 32.66 Mn |
| Sep 30, 2019 | 133.28 Mn |
| Mar 31, 2019 | 137.44 Mn |
| Dec 31, 2018 | 2.18 Mn |
| Sep 30, 2018 | 78.26 Mn |
| Mar 31, 2018 | 75.04 Mn |
| Dec 31, 2017 | 77.90 Mn |
| Dec 31, 2016 | 1.16 Mn |